Many investors are attracted to Pfizer (NYSE:PFE), Merck, and Johnson & Johnson -- the only pharmaceutical companies in the Dow Jones Industrial Average -- for their robust dividends. The cash these companies generate, however, is largely dependent on patent protection for the companies' branded pharmaceutical products. When patents expire, revenue quickly erodes in the face of generic competition.
Pfizer is still dealing with the patent expiration of its megablockbuster drug Lipitor, but are there additional expirations looming in the near future? And how does Pfizer compare with peer Eli Lilly (NYSE:LLY)? In the following video, taken from the Motley Fool's health care show Market Checkup, analysts David Williamson and Max Macaluso discuss these topics in detail.
David Williamson owns shares of Pfizer. Max Macaluso, Ph.D., has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Dividend Stocks That Pay You More Than ExxonMobil Does
The oil giant pays its shareholders well, but there are opportunities out there for even higher payouts.
The 1 Word That Explains Why Pfizer's Future Looks Brighter Than Its Past
The big drugmaker had a clear message at the J.P. Morgan Healthcare Conference -- and it's a good one for investors.
3 Scorching-Hot Healthcare Stocks -- Are They Buys?
These three companies gained at least 400% in 2017. Can the good times continue?